Recombinant Human CLEC9A Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02355P-100UG
Human CLEC9A on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human CLEC9A Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02355P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human CLEC9A Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Lys57-Val241. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q6UXN8 |
Target Symbol | CLEC9A |
Synonyms | CD370; CLEC9A; 9830005G06Rik; DNGR-1; HEEE9341; UNQ9341 |
Species | Human |
Expression System | HEK293 |
Tag | N-hFc |
Expression Range | Lys57-Val241 |
Mol. Weight | The protein has a predicted MW of 48.5 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human CLEC9A, hFc Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Biotinylated Anti-CLEC9A Antibody, hFc Tag with the EC50 of 5.9ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients. |